POINT Competitors

Delisted . USA . 
Stock . POINT Biopharma Global
PNTDelisted Stock  USD 9.06  0.10  1.09%   
POINT Biopharma Global competes with Oric Pharmaceuticals, Lyra Therapeutics, Inhibrx, ESSA Pharma, and Crinetics Pharmaceuticals; as well as few others. The company runs under Biotechnology sector within Health Care industry. Analyzing POINT Biopharma competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of POINT Biopharma to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of POINT Biopharma competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
9.069.069.06
Details
Intrinsic
Valuation
LowRealHigh
7.767.769.97
Details
Naive
Forecast
LowNextHigh
8.948.948.94
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
8.929.279.62
Details

POINT Biopharma Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between POINT Biopharma and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of POINT and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of POINT Biopharma Global does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
IMTX
+ 0.85
ALXO
ALXO
+ 0.78
LYRA
IMTX
+ 0.75
EPIX
AVTE
+ 0.72
CRNX
IMTX
+ 0.61
LYRA
ALXO
+ 0.59
EPIX
  
High negative correlations   
AVTE
- 0.89
EPIX
AVTE
- 0.83
IMTX
AVTE
- 0.8
ALXO
IMTX
- 0.7
CRNX
ALXO
- 0.59
CRNX
CRNX
- 0.57
EPIX

Risk-Adjusted Indicators

There is a big difference between POINT Stock performing well and POINT Biopharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze POINT Biopharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
ORIC  2.87 (0.10) 0.00  0.07  4.26 
(2.63)
 6.04 
(5.18)
 23.18 
LYRA  4.16 (0.70) 0.00 (0.40) 0.00 
 0.00 
 8.00 
(10.00)
 41.07 
INBX  2.27  0.08  0.01  0.25  2.71 
(2.75)
 4.92 
(6.11)
 16.80 
EPIX  4.69 (0.64) 0.00  5.25  0.00 
 0.00 
 9.30 
(6.45)
 84.61 
CRNX  1.71 (0.01)(0.01) 0.11  2.43 
(1.68)
 3.67 
(3.45)
 16.75 
ALXO  3.50 (0.92) 0.00 (0.31) 0.00 
 0.00 
 7.53 
(7.76)
 22.71 
IMTX  1.96 (0.62) 0.00 (0.93) 0.00 
 0.00 
 3.46 
(4.87)
 22.12 
BCAB  4.31 (0.24) 0.00 (0.03) 0.00 
 0.00 
 12.86 
(7.59)
 31.41 
AVTE  2.55  0.49  0.19  0.61  2.13 
(3.41)
 5.58 
(3.86)
 19.11 
CERE  0.77  0.10 (0.04)(0.31) 0.94 
(1.02)
 1.91 
(1.59)
 6.40 
All Fundamental Data

POINT Biopharma Competitive Analysis

The better you understand POINT Biopharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, POINT Biopharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across POINT Biopharma's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
PNT ORIC LYRA INBX EPIX CRNX ALXO IMTX BCAB AVTE
 1.09 
 9.06 
POINT
 2.92 
 9.87 
Oric
 5.56 
 0.19 
Lyra
 5.54 
 14.86 
Inhibrx
 1.64 
 1.80 
ESSA
 0.05 
 56.09 
Crinetics
 4.26 
 1.47 
Alx
 0.13 
 7.59 
Immatics
 5.73 
 1.66 
Bioatla
 0.75 
 2.68 
Aerovate
Market Volatility
(90 Days Market Risk)
Very steady
Somewhat reliable
Very risky
Not too volatile
Very risky
Very steady
Relatively risky
Somewhat reliable
Risky
Somewhat reliable
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Weak
Very Weak
Very Weak
Very Weak
Good
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Low
Quite High
Very High
About Average
Low
Very High
Low
Low
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Buy
Strong Sell
Hold
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Hold
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Hold
Strong Sell
Cautious Hold
Strong Sell
Strong Buy
Current Ratio
10.9
18.72
12.4
7.51
43.43
15.94
13.23
2.95
7.48
40.85
Net Asset
578.32 M
252.01 M
142.6 M
307.89 M
149.12 M
635.35 M
242.55 M
509.96 M
119.66 M
127.42 M
Profit Margin
0.4
N/A
N/A
1019.74
N/A
N/A
N/A
-1.04
N/A
N/A
EBITDA
127.32 M
(109.75 M)
(65.25 M)
(206.69 M)
(26.46 M)
(221.51 M)
(158.4 M)
(88.93 M)
(122.24 M)
(81.31 M)
Operating Margin
-10.62
N/A
-49.43
N/A
N/A
-295.25
N/A
-1.42
-1.02
N/A
Current Valuation
1 B
407.49 M
(3.93 M)
9.32 M
(49.12 M)
4.39 B
(64.37 M)
425.85 M
19.39 M
(11.38 M)
Price To Book
3.13
2.47
0.6
1.14
0.63
6.24
0.54
2.3
3.3
0.95
Retained Earnings
39.01 M
(434.93 M)
(311.36 M)
(613.73 M)
(179.46 M)
(653.7 M)
(486.27 M)
(597.29 M)
(416.26 M)
(163.42 M)
Current Asset
N/A
N/A
12.7 M
N/A
10.02 M
44.96 M
N/A
N/A
N/A
N/A
Beta
-0.003
1.12
-0.036
2.88
1.84
0.62
1.04
0.78
1.02
1.0
Number Of Employees
129
112
88
166
50
290
89
542
65
51
Shares Outstanding
106.57 M
70.57 M
65.46 M
14.48 M
44.39 M
92.74 M
52.74 M
121.55 M
48.35 M
28.87 M
Cash Flow From Operations
183.52 M
(85.69 M)
(63.3 M)
(193.31 M)
(19.78 M)
(166.31 M)
(130.36 M)
18.23 M
(104.02 M)
(56.78 M)
Total Debt
3.56 M
10.21 M
26.88 M
210.14 M
80.33 K
51.73 M
17.2 M
15.4 M
2.46 M
675 K
Return On Equity
0.26
-0.46
-1.86
-20.31
-0.2
-0.4
-0.99
-0.24
-1.39
-0.82
Z Score
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
0.17
-0.29
-0.42
-0.57
-0.15
-0.24
-0.49
-0.12
-0.5
-0.49
Number Of Shares Shorted
2.64 M
11.65 M
2.04 M
976.67 K
1.15 M
6.94 M
7.84 M
6.69 M
4.87 M
549.75 K
Book Value Per Share
4.01
3.88
0.32
15.15
2.9
10.3
2.59
2.66
0.48
2.79
Current Liabilities
N/A
N/A
4.82 M
N/A
3.63 M
2.41 M
N/A
N/A
N/A
N/A
Total Asset
578.32 M
252.01 M
142.6 M
307.89 M
149.12 M
635.35 M
242.55 M
509.96 M
119.66 M
127.42 M
Debt To Equity
0.012
0.054
0.008
4.22
0.001
0.009
0.021
0.13
0.028
0.008
Short Ratio
0.98
29.34
1.54
14.06
30.53
8.47
11.81
8.76
2.76
0.36
Target Price
12.5
18.73
1.25
15.0
13.2
73.29
9.33
17.4
10.67
2.33
Shares Owned By Institutions
48.91
90.88
58.82
67.49
81.18
94.68
92.44
68.72
42.64
99.98
Market Capitalization
1.33 B
676.74 M
12.37 M
203.82 M
81.23 M
5.2 B
74.37 M
922.56 M
75.9 M
76.81 M
Price To Earnings To Growth
N/A
N/A
1.61
N/A
N/A
N/A
N/A
3.0
N/A
N/A
Price To Earning
N/A
N/A
N/A
N/A
-1.12
-12.03
N/A
44.61
N/A
0.64
Price To Sales
5.45
N/A
8.41
120.82
N/A
5003.72
5906.24
13.02
6.9
N/A
Net Income
98.29 M
(100.7 M)
(62.68 M)
(241.36 M)
(26.58 M)
(214.53 M)
(160.81 M)
(96.99 M)
(123.46 M)
(75.52 M)
Earnings Per Share
1.1
-1.82
-1.49
119.39
-0.62
-3.7
-2.97
-0.64
-1.7
-2.99
Shares Owned By Insiders
14.97
9.12
0.65
23.54
2.26
1.79
1.91
22.17
10.75
0.018
Revenue
226.58 M
N/A
1.56 M
1.8 M
N/A
4.01 M
N/A
54 M
N/A
N/A
Working Capital
451.08 M
192.14 M
85.22 M
239.05 M
145.3 M
530.21 M
152.66 M
292.82 M
88.06 M
106.59 M
Cash And Equivalents
199.43 M
227.06 M
120.67 M
176.38 M
174.6 M
408.51 M
313.37 M
324.38 M
178.12 M
151.99 M
Cash Per Share
2.21
5.74
3.79
4.52
3.96
7.6
7.69
5.0
4.77
6.22
Gross Profit
N/A
N/A
(34.23 M)
(107.99 M)
N/A
(125.49 M)
107 K
172.83 M
(79.35 M)
N/A
Day Typical Price
9.03
9.87
0.19
15.1
1.82
56.48
1.5
7.61
1.64
2.68
Accumulation Distribution
0.0328
25711.31
0.1
5487.54
7791.52
15073.78
118767.0
0.0373
57026.54
7560.4
Market Facilitation Index
0.3
0.0
0.02
0.0
N/A
0.0
N/A
0.29
N/A
N/A
Daily Balance Of Power
(0.33)
0.7179
0.5
0.7723
(0.43)
0.0201
0.3529
0.0345
0.6923
0.2222
Period Momentum Indicator
(0.10)
0.28
0.01
0.78
(0.03)
0.03
0.06
0.01
0.09
0.02
Rate Of Daily Change
0.99
1.03
1.06
1.06
0.98
1.0
1.04
1.0
1.06
1.01
Day Median Price
9.01
9.87
0.19
15.22
1.84
56.68
1.52
7.63
1.63
2.69
Price Action Indicator
N/A
0.14
0.005
0.035
(0.05)
(0.57)
(0.01)
(0.03)
0.08
0.005
Relative Strength Index
46.91
58.05
55.21
58.36
21.08
67.51
45.18
38.79
62.79
70.26
Coefficient Of Variation
1421.48
2770.13
(1,207)
1847.91
(1,601)
2250.02
(706.95)
(552.64)
(13,175)
583.83
Mean Deviation
2.17
2.87
4.16
2.27
4.69
1.71
3.5
1.96
4.31
2.55
Jensen Alpha
0.2529
(0.10)
(0.70)
0.0835
(0.64)
(0.01)
(0.92)
(0.62)
(0.24)
0.4909
Total Risk Alpha
(0.27)
(0.48)
(1.54)
(0.34)
(2.27)
(0.28)
(1.39)
(1.03)
(0.97)
0.0402
Sortino Ratio
0.0297
0.002
N/A
0.0141
N/A
(0.01)
N/A
N/A
N/A
0.1893
Downside Variance
7.07
20.42
N/A
8.19
N/A
6.43
N/A
N/A
N/A
6.76
Standard Deviation
2.98
3.87
6.36
3.16
10.27
2.4
4.61
3.0
5.82
3.64
Kurtosis
2.72
1.88
5.6
1.48
38.83
3.24
0.5055
9.0
1.23
3.8
Potential Upside
5.7
6.04
8.0
4.92
9.3
3.67
7.53
3.46
12.86
5.58
Treynor Ratio
(0.45)
0.067
(0.40)
0.251
5.25
0.1069
(0.31)
(0.93)
(0.03)
0.6077
Maximum Drawdown
20.11
23.18
41.07
16.8
84.61
16.75
22.71
22.12
31.41
19.11
Variance
8.89
15.01
40.51
9.99
105.53
5.75
21.29
9.0
33.86
13.22
Market Risk Adjusted Performance
(0.44)
0.077
(0.39)
0.261
5.26
0.1169
(0.30)
(0.92)
(0.02)
0.6177
Risk Adjusted Performance
0.0614
0.0357
(0.05)
0.0491
(0.04)
0.0409
(0.10)
(0.13)
0.0029
0.1393
Skewness
0.1642
(0.67)
(0.91)
0.3218
(5.41)
(0.05)
0.1006
(1.87)
0.7904
1.45
Semi Deviation
2.58
4.26
N/A
2.71
N/A
2.43
N/A
N/A
N/A
2.13
Information Ratio
0.0265
0.0023
(0.10)
0.0127
(0.08)
(0.01)
(0.17)
(0.22)
(0.03)
0.1353
Value At Risk
(3.78)
(5.18)
(10.00)
(6.11)
(6.45)
(3.45)
(7.76)
(4.87)
(7.59)
(3.86)
Expected Short fall
(2.52)
(2.63)
N/A
(2.75)
N/A
(1.68)
N/A
N/A
N/A
(3.41)
Downside Deviation
2.66
4.52
N/A
2.86
N/A
2.53
N/A
N/A
N/A
2.6
Semi Variance
6.65
18.17
N/A
7.33
N/A
5.89
N/A
N/A
N/A
4.54

POINT Biopharma Competition Performance Charts

Five steps to successful analysis of POINT Biopharma Competition

POINT Biopharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by POINT Biopharma Global in relation to its competition. POINT Biopharma's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of POINT Biopharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact POINT Biopharma's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to POINT Biopharma Global, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your POINT Biopharma position

In addition to having POINT Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run SRI Sustainable Growth Thematic Idea Now

SRI Sustainable Growth
SRI Sustainable Growth Theme
Socially responsible investments that include companies making a positive, sustainable or social impact and exclude those making a negative impact. The SRI Sustainable Growth theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize SRI Sustainable Growth Theme or any other thematic opportunities.
View All  Next Launch
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Other Consideration for investing in POINT Stock

If you are still planning to invest in POINT Biopharma Global check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the POINT Biopharma's history and understand the potential risks before investing.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY